Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Simnotrelvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Simnotrelvir is an oral antiviral for COVID-19, developed by Simcere Pharmaceutical with the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology, and sold in China as 先诺欣® (Xiannuoxin). It comes as a combination pack of simnotrelvir tablets and low-dose ritonavir tablets, which are swallowed together for five days.
China's National Medical Products Administration (NMPA) first approved it with conditions on 28 January 2023 and converted this to a regular (full) approval in July 2024. It is approved for adults with:
As the virus keeps changing, the label notes that its effect against newer strains needs to be kept under study. It is a prescription infection medicine and should only be taken on a doctor's advice.
The coronavirus needs an enzyme called the 3CL (main) protease to cut its proteins into working parts before it can make copies of itself. Simnotrelvir blocks that enzyme, so the virus cannot multiply. Low-dose ritonavir slows the breakdown of simnotrelvir in the body, which keeps its blood level high enough to work.
The phase 2/3 trial, published in the New England Journal of Medicine in 2024, included 1,208 adults with mild to moderate COVID-19 at 35 sites in China. Almost all were vaccinated, and about half had at least one risk factor for severe illness. In people who started within 72 hours of symptoms, all 11 tracked symptoms cleared about a day and a half sooner than with placebo (median 180.1 vs 216.0 hours). By day 5, the viral load had fallen by an extra 1.51 log10 copies/mL. No one in either group developed severe COVID-19 or died, so the trial could not measure an effect on serious illness.
Simnotrelvir must always be taken with ritonavir. No dose change is needed for older adults or for mild to moderate liver impairment. For moderate kidney impairment (eGFR 30 to below 60 mL/min) the dose is lowered to 1 simnotrelvir tablet with 1 ritonavir tablet every 12 hours. It should not be used with severe liver or kidney impairment (eGFR below 30), including dialysis.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Drug interactions (most important): the ritonavir in the pack strongly blocks the liver enzyme CYP3A. This can push up the levels of many everyday medicines, including some heart, blood-pressure, cholesterol, pain and sedative medicines, sometimes to dangerous levels. Some other medicines and herbal remedies can lower simnotrelvir levels and stop it working. The Chinese leaflet lists medicines that must not be combined with it, so give your doctor a full list of everything you take before starting.
Overall: in the trial, side effects were reported in 29.0% of people on simnotrelvir and 21.6% on placebo, mostly mild or moderate. The most frequent drug-related ones were a rise in triglycerides (4.3% vs 2.1%), a fall in neutrophils (1.9% vs 0.2%) and diarrhoea (1.7% vs 1.1%). There were no serious side effects in the simnotrelvir group, and 1.2% stopped treatment. It has not been tested in children under 18.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit. Since treatment should start within 3 days of the first symptoms, please contact us as early as possible.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. NPP also arranges other antiviral medicines that are not sold in India, such as Livtencity.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box is one full 5-day course: five blister strips, one per day, each holding 4 simnotrelvir and 2 ritonavir tablets. The label asks for the pack to be kept sealed at no more than 30°C, so it travels in its original packaging under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid doctor's prescription.
Our New Delhi dispatch point keeps transit short, which matters for a course that should begin soon after symptoms appear.
Doctors in Mumbai can send the prescription, test report and kidney result together so the request is checked in one go.
Patients in Bangalore can have the pack delivered to their home or clinic once the paperwork is verified.
We confirm the expected delivery time before ordering, so the doctor can judge whether it still fits the treatment window.
Physicians in Hyderabad can request the medicine for a named patient after reviewing their other medicines for interactions.
For Kolkata and the eastern states, shipments are routed to arrive as quickly as the import process allows.
Patients in Pune can use the same documented import route, with updates at each stage.
The treating doctor can share the prescription and medicines list with us to begin the import.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.
Patients in Rajasthan can receive the course without travelling, as long as the import is in their name.
We coordinate delivery for patients treated at public and private hospitals across Uttar Pradesh.
Patients across Kerala can have the pack delivered to their home or hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
